Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
MoonLake Immunotherapeutics experienced a significant setback as its investigational interleukin-17 (IL-17) inhibitor, sonelokimab, failed to meet the primary endpoint in one of two phase 3 studies for hidradenitis suppurativa (HS). The news caused the company's stock to crash by 87% in premarket trading on Monday.
Crystalys Therapeutics, a San Diego-based biotech company, has burst onto the pharmaceutical scene with a substantial $205 million Series A financing round. The company, founded in 2022, aims to develop a novel treatment for gout, a painful form of arthritis affecting millions worldwide.
Merck's pulmonary arterial hypertension (PAH) drug Winrevair has demonstrated significant efficacy in recent clinical trials, positioning it as a potential game-changer in PAH treatment. The pharmaceutical giant has unveiled compelling data from multiple studies, showcasing the drug's ability to reduce clinical worsening events and improve patient outcomes.
Pharmaceutical companies are increasingly turning to innovative softgel and lipid-based formulations to enhance the performance of challenging therapeutics. Recent developments in this technology are providing solutions for drugs with poor solubility, stability issues, and bioavailability concerns.
September proved to be a pivotal month for the pharmaceutical industry, with the U.S. Food and Drug Administration (FDA) issuing a series of significant decisions that will shape the landscape of drug development and patient care. From bolstering the future of blockbuster immunotherapies to addressing ultra-rare diseases, the agency's actions have far-reaching implications for patients, healthcare providers, and pharmaceutical companies alike.
As 2025 enters its final quarter, the pharmaceutical industry anticipates a series of pivotal FDA decisions that could reshape treatment landscapes across multiple therapeutic areas. From rare genetic disorders to oncology, these rulings have the potential to introduce novel therapies and expand indications for existing treatments.
Siemens Healthineers, a leading medical technology company, has announced two significant robotics partnerships aimed at enhancing precision and efficiency in medical imaging and interventional procedures. These collaborations mark a notable expansion of the company's footprint in the rapidly evolving field of medical robotics.
In a significant development for the pharmaceutical industry, GSK CEO Emma Walmsley has announced her decision to step down from her position in January. This move represents a notable shift in the landscape of gender diversity at the highest levels of pharmaceutical leadership.
Emma Walmsley, who has been at the forefront of GSK since 2017, will officially leave her post on January 1, 2026. During her tenure, Walmsley oversaw significant changes at GSK, including the successful demerger of the consumer health unit Haleon in 2022, which allowed the company to focus on its biopharma and vaccines divisions.
Biogen, a leading pharmaceutical company, has announced the complete discontinuation of its adeno-associated virus (AAV) based gene therapy programs, resulting in a significant staff reshuffle within the affected unit. This move comes as part of the company's broader cost-cutting initiative aimed at generating $1 billion in savings by 2025.
Applied Therapeutics has signaled potential progress in its development of govorestat, an aldose reductase inhibitor targeting sorbitol dehydrogenase deficiency (SORD), a rare genetic condition. The company recently posted details of a new confirmatory study on clinicaltrials.gov, suggesting a possible agreement with the FDA on the drug's path forward.
Danish pharmaceutical company Genmab has announced its acquisition of Netherlands-based biotech firm Merus for $8 billion, marking a significant move in the oncology drug development landscape. The deal, which is expected to close in the first quarter of 2026, centers around Merus' promising bispecific antibody petosemtamab, which has shown potential as a best-in-class treatment for head and neck cancer.
